High prevalence of gastroenterological disorders, rising trend in the use of minimally invasive procedure and technological advancement in stents are likely to boost the growth of global gastrointestinal stent market. Gastrointestinal stenting is a common palliative intervention performed to recanalize part of a malignant occlusion involving the oesophagus, biliary tree and colon as well as a means to manage gastrointestinal leakage.
The increasing geriatric population and the rising incidences of colorectal and oesophageal cancer are also adding to the demands of gastrointestinal stents. Stent technologies such as self-expandable metal stents (SEMS), and biodegradable stents improve patient prognosis leading to lesser surgical procedures.
The growth is measured at 5.3% CAGR from USD 530.6 million in 2025 to USD 889.4 million by 2035. Long-Term Market Trend: Growth of the market in the long run will be driven by factors such as increasing health care infrastructure, more endoscopic procedures and increasing use of stents in palliative care.
Key Market Metrics
| Metric | Value |
|---|---|
| Market Size in 2025 | USD 530.6 Million |
| Projected Market Size in 2035 | USD 889.4 Million |
| CAGR (2025 to 2035) | 5.3% |
Explore FMI!
Book a free demo
The rising prevalence of gastrointestinal disorders and the high healthcare expenditure in North America continue to make it a leading market segment for gastrointestinal stents. The USA is the largest market, with high demand for minimally invasive procedures and growing technology in stenting designs.
Factors contributing to the growth of the gastrointestinal stent market in Europe include high cancer prevalence, positive reimbursement conditions as well as increased uptake of endoscopic stenting. Flexible market spending on global healthcare services in response and top health policy spending approaches have involved in support, which is advances because of high technologies are cost-effective.
Major growth in the Asia-Pacific region is led by increasing investments in health care, increasing awareness of minimally invasive treatment options and growing patient population. Countries like China, India, and Japan are also expanding fast alongside the increasing quality of care and the increased use of gastrointestinal stents in hospitals and ambulatory surgical centres
Challenges
High Procedure Costs, Risk of Complications, and Regulatory Hurdles
The market is witnessing a notable growth rate, nevertheless the high cost of GI stent placement and post-operative care and visit to specialty centres is a matter of concern for the market as affordability is an issue for developing healthcare markets. Additionally, risks including stent migration, occlusion and perforation fester against the broader adoption of stent therapy, leaving room for innovation in the design and materials of stents.
Moreover, stringent regulatory clearances from various organizations such as the FDA, EMA, and regional health agencies mandate comprehensive clinical trials, as well as adherence to changing medical device standards, prolonging the time to market for novel stent technologies.
Opportunities
Increase in Minimally Invasive Procedures, Increasing Geriatric Population, and Biodegradable Stent Innovations
The market is growing despite challenges owing to the rising preference for minimally invasive procedures that require shorter recovery time as well as lower hospital stays. The growth of the advanced stenting system is driven by the increasing geriatric population, the rising prevalence of gastrointestinal cancers, the rising number of strictures, and gastrointestinal obstruction.
Biodegradable and drug-eluting stents are further promising the options to mitigate risks of permanent metallic stents and the long-term concerns with permanent metallic stents. The market potential is further boosted by innovations in smart stent technologies powered by artificial intelligence real-time monitoring.
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Compliance with FDA, CE Mark, and local medical device regulations. |
| Consumer Trends | Rising adoption of self-expandable metallic stents (SEMS) for GI obstructions. |
| Industry Adoption | Used primarily in cancer-related obstructions and palliative care. |
| Supply Chain and Sourcing | Dependence on metallic alloys and polymer-based stent manufacturing. |
| Market Competition | Dominated by established medical device manufacturers. |
| Market Growth Drivers | Demand fuelled by rising gastrointestinal cancer cases and growing awareness of stenting solutions. |
| Sustainability and Environmental Impact | Initial focus on reducing material waste in medical device manufacturing. |
| Integration of Smart Technologies | Basic coated metallic stents for long-term implantation. |
| Advancements in Stent Technology | Development of next-generation nitinol and polymer-coated stents. |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Stricter biocompatibility, long-term safety, and real-time stent monitoring requirements. |
| Consumer Trends | Growth in biodegradable, drug-eluting, and AI-monitored gastrointestinal stents. |
| Industry Adoption | Increased application in early-stage GI disorders, chronic strictures, and functional GI diseases. |
| Supply Chain and Sourcing | Shift toward biodegradable materials, 3D-printed stents, and nanotechnology-enhanced coatings. |
| Market Competition | Entry of biotech firms specializing in personalized stent design and AI-powered stenting solutions. |
| Market Growth Drivers | Accelerated by smart stent technology, improved stent coatings, and personalized GI interventions. |
| Sustainability and Environmental Impact | Increased use of bioresorbable stents, green manufacturing processes, and recyclable medical devices. |
| Integration of Smart Technologies | Expansion into sensor-equipped stents, AI-powered obstruction detection, and remote patient monitoring. |
| Advancements in Stent Technology | Evolution toward smart, biodegradable, and patient-specific stents using AI-driven diagnostics. |
The growing adoption of self-expandable as well as drug-eluting stents due to the high market penetration of prominent medical device manufacturers as well as favorable reimbursement policies is positively influencing the market. Moreover, fast advancements in bioresorbable stents and smart diagnostic implants are driving market innovation.
In addition, the rising preference for outpatient endoscopic treatment and increasing establishment of ambulatory surgical centre is further supporting the market growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 5.4% |
Market growth in the UK is stable due to investment from the government in cancer treatment, increasing adoption for endoscopic surgery, and technological advancements in GI stents. With the National Health Service (NHS) programs for early cancer detection and minimal invasiveness, self-expanding stents are more and more applied for oesophageal and colorectal obstructions.
Meanwhile,the increasing adoption of AI-assisted diagnostics and robotic-assisted endoscopic services is generating a plethora of opportunities for next-generation GI stents.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 5.2% |
Strict medical device regulations, increasing demand for minimally invasive treatment options, and rising cases of gastrointestinal cancer are key factors driving the growth of the gastrointestinal stent market in Europe. Countries such as Germany, France, and Italy are at the forefront of advanced endoscopic procedures, increasing the need for high-performance, drug-coated stents.
The European Union Medical Devices Regulation (EU MDR) is forcing the hand of manufacturers to create stents that are safer, more durable, and biocompatible. Furthermore, introduction of biodegradable stents and smart monitoring devices is creating new opportunities for market growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| EU | 5.3% |
The Japan gastrointestinal stent market is still growing driven by the fast-growing elderly population, rising adoption of high-tech endoscopic treatment and high inclination towards early cancer detection. All these factors contribute to the growing development of sensor-embedded and biodegradable stents on account of the country’s advanced medical infrastructure and AI-integrated diagnostic solutions. Moreover, the high incidence of stomach and colonic malignancy is augmenting the demand for self-expanding metallic and polymer-coated stents. Patients are also benefiting from advances in nanotechnology-based stent coatings.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 5.3% |
The gastrointestinal stent market is expected to be driven by factors such as increasing investments pertaining to medical device innovation, rising preference towards endoscopic treatments for a broad spectrum of gastrointestinal diseases, and increasing incidence rate of cancers in South Korea.
The demand for next-generation GI stents in the country is mainly supported by strong healthcare infrastructure in the country, increasing penetration of AI-based medical technologies, and government-supported cancer screening programs. Furthermore, the partnerships between medical device companies and biotech companies are tackling chronic gastrointestinal diseases and developing bioresorbable and drug-eluting stents.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 5.4% |
The gastrointestinal stent market is primarily driven by the domination of the biliary and duodenal stent segments, as healthcare providers are adopting stenting procedures to relieve obstructions, improve patient outcomes, and reduce the use of invasive surgeries. Verstects are an important component of making digestive tract function, and reducing complications and maximizing patient comfort.
Biliary stents are performing as one of the leading segments in the market for gastrointestinal stent devices as these devices help in relieving bile duct obstruction caused by malignancies, strictures, and gallstones. Biliary stents have emerged as a minimally invasive alternative to surgical intervention, allowing for immediate relief of bile flow obstruction and minimization of clinical consequences like jaundice and liver failure.
Marketplace adoption is mainly driven by the increasing demand for bile duct decompression procedures such as the market introduction of stents which are designed with advanced anti-migration capabilities with longer patency rates and drug-eluting coatings.
Numerous studies indicate that the endoscopic management of obstructive jaundice is performed in over 60% of patients with biliary obstruction; the endoscopic placement of plastic or metal stents is a first-line treatment to enhance the quality of life of patients with obstructive jaundice while reducing the risk of a more invasive procedure.
Also, growing focus on pancreatic cancer therapies including biliary stents utilized for palliative care and preoperative biliary drainage has bolstered the market growth pertaining to ensure better management of obstructive jaundice and recovery post-care processes.Adoption has been further accelerated with AI-assisted endoscopic guidance, including real time stent placement, automatic flow restoration analysis, and predictive stent failure detection.
The evolution of biodegradable and drug-coated biliary stents with sustained drug release mechanisms, better biocompatibility as well as improved resistance to bacterial biofilm formation, have optimized market growth, yielding improved long-term outcomes for patients suffering from benign and malignant biliary diseases.
While hypothetically advantageous for minimally invasive bile duct decompression, prolonged stent patency, and decreased risk of infection, the dominant biliary stent segment is confronted with realistic limitations during bile duct intervention, stent occlusion with migration risk, and less customization for complex anatomical variations.
But, advanced technologies with self-expanding stent designs, AI-based stent placement methodology, and bioresorbable polymer coatings are augmenting the efficacy, with respect to which there is no running out of market expansion for biliary stent.
The healthcare sector has witnessed widespread adoption of duodenal stents, especially among patients suffering from malignant gastric outlet blockages, as healthcare professionals are encouraged to opt for nonsurgical therapies for the treatment of gastrointestinal obstruction. Duodenal stents open up the intestines without the increased risks that come with surgical bypass procedures.
The increased adoption of palliative treatment of gastric and duodenal obstructions, supported by stents with increased radial strength, anti-tumor ingrowth coating, and accuracy placement technology, has also led to market acceptance. In patients with advanced malignancies, two case series have shown that over 55% of all gastric outlet obstruction cases are handled with duodenal stenting, which is performed in order to increase food intake and patient overall well-being.
Implementation of palliative care measures, including stent-assisted enteral feeding, non-surgical gastrointestinal decompression, and endoscopic tumor bypass procedures, has created new avenues for market growth by allowing provision of nutritional support and symptom management for patients diagnosed with late-stage malignancies.
The use of efficient fluoroscopic navigation with active obstruction detection and dynamic stent positioning analysis and adaptive expansion monitoring has additionally stimulated the incorporation, thus ensuring higher procedural success rate and reduced complications.
Next-generation duodenal stents (constructed of ultra-flexible nitinol, had integrated anti-reflux valve, coated with bioactive stent such, to increase stent durability); upgraded bioactive stent technology adds to the revenue growth across the market as it has been proved by researchers to achieve immediate improved stent patency in gastroparesis and biliary obstruction, facilitating the complexity of both continuous and intermittent structures.
Even though it has superior performance compared to its traditional counterparts in the field of urethral obstruction, the duodenal stent segment is challenged by technical issues around stent occlusion from tumor ingrowth, reduced long term efficacy when patients have progressive diseases and post-stent-placement complications like nausea and pain.
However, dual-layered stent structures, AI-powered patency monitoring of stents, and the development of bio-resorbable stents are improving the outcome without any adverse effects, which will continue to expand the duodenal stents market in the gastrointestinal stents market.
These segments include self-expanding metal stents (SEMS), and plastic stents among others and drive the growth of the market wherein healthcare professionals are looking for the stents with better durability, flexibility as well as patency for gastrointestinal stents.
Self-expanding metallic stents for longer-term gastrointestinal decompression have been recognized more than those offered by other technique based on superior radial force, resistance to compression and patency on malignant obstruction. Compared with plastic stents, SEMS have superior expansion properties and less migration and occlusion.
The increasing acceptance of long-lasting gastrointestinal stenting solutions, such as nitinol-based SEMS with anti-migration anchoring, drug-eluting capabilities, as well as self-adaptive expansion has accelerated market adoption. For their enhanced success rate and durability, most of the self-expanding metal stents are used for performing such procedures accounting for more than 50% of all gastrointestinal stent insertions for malignant obstructions.
The growth of minimally invasive gastrointestinal procedures, including stent-assisted endoscopic decompression, tumor bypass strategies, and combined SEMS-assisted palliative intervention methods, fortifying the market and providing better clinical outcomes with shorter hospitalizations, is anticipated to augment market penetration at large.
Real-time stent dilation measurements with occlusion prediction algorithms and automated stent adaption have been integrated into AI-driven stent performance monitoring, increasing the adoption even more and guaranteeing greater precision and lower complication rates.
Advances into hybrid SEMS designs (eg, polymer-coated anti-reflux systems, dual-layer mesh reinforcement, and biodegradable stent integration), have enhanced overall market growth with optimized flexibility and compatibility with evolving gastrointestinal therapeutic regimens.
Even though it has more long-term patency, a better radial force, and better tumour bypass, the SEMS segment is challenged with expensive and low-removable options, as well as the risk of excessive growth of tissues in some cases. Nonetheless, advancements in fully covered SEMS, AI-assisted dilation control, and bioresorbable metallic alloys are leading the way, guaranteeing that self-expanding metallic stents will continue to flourish in the local treatment of the gastrointestinal tract.
Healthcare providers focus on cost-effective solutions for temporary obstruction management, leading to strong market adoption of plastic stents, primarily for short-term biliary and duodenal decompression. Compared to SEMS, plastic stents are also easier to remove and are better suited for preoperative drainage as well as for providing temporary relief of luminal obstruction.
Increased demand for affordable stenting solutions with high-flow plastic stents with a high patency rate, anti-sludge coating, and different customized diameter openings are contributing to the market adoption of plastic stents. Plastic stents are used in >45% of benign biliary strictures, largely because of the lower costs and ease of placement.
The growth of preoperative biliary drainage procedures, including plastic stents to relieve jaundice, obstruction by gallstones, and preparation for liver surgery, has further consolidated the growth of the market and facilitated the management of patients and outcomes of the surgery.
Artificial intelligence driven stent selection tools that provide real-time obstruction assessment and automate stent size recommendation and dynamically detect stent migration have propelled adoption even further, ensuring greater overall success of the procedure.
Biodegradable plastic formulations, hybrid reinforced structures, and bioactive polymer coatings in next-generation plastic stents will drive the market, promising enhanced safety and performance for short-term stenting applications.
The plastic stents segment can gain from factors such as low costs, and brief-term arrest obstruction relief, hindrances that can stand for higher occlusion rates, low durability, and more frequent stent substitute requirements. But advances in bioresorbable plastic stents, AI-powered stent placement optimization, and anti-microbial surface treatments are enhancing functionality, with plastic stents continuing to carve out a niche space within the broader gastrointestinal stent market.
Increasing prevalence of gastrointestinal cancers, growing preference for minimally invasive procedures, advancements in artificial intelligence (AI) powered imaging and stent placement technologies, and increasing healthcare expenditure is fuelling the growth of the GI stents market. The demand for self-expandable metallic and plastic stents in the management of oesophageal, biliary, and colorectal obstructions is growing, supported by advancements in biodegradable and drug-eluting stents in the business.
The key players in the industry are concentrated on AI-assisted stent deployment, next-generation biocompatible materials, and endoscopic stent placement solutions. Key players comprise medical device manufacturers, biotechnology companies, and healthcare technology companies exhibiting innovations in precision, customized gastrointestinal stent techniques for patients.
Market Share Analysis by Key Players & Gastrointestinal Stent Manufacturers
| Company Name | Estimated Market Share (%) |
|---|---|
| Boston Scientific Corporation | 22-26% |
| Cook Medical | 14-18% |
| Medtronic Plc | 12-16% |
| Becton, Dickinson and Company (BD) | 8-12% |
| Taewoong Medical Co., Ltd. | 6-10% |
| Other GI Stent Providers (combined) | 30-40% |
| Company Name | Key Offerings/Activities |
|---|---|
| Boston Scientific Corporation | Develops AI-powered self-expanding metal and plastic stents for esophageal, biliary, and colorectal applications, with advanced drug-eluting technology. |
| Cook Medical | Specializes in endoscopic GI stent systems with AI-enhanced placement accuracy and biodegradable stent innovations. |
| Medtronic Plc | Focuses on AI-assisted stent design, advanced fluoroscopic guidance for precision placement, and next-generation biocompatible materials. |
| Becton, Dickinson and Company (BD) | Provides AI-driven minimally invasive stent solutions for biliary and colonic obstructions, integrating real-time patient monitoring technology. |
| Taewoong Medical Co., Ltd. | Offers high-performance GI stents with AI-enhanced deployment mechanisms and custom-sized solutions for personalized patient care. |
Key Market Insights
Boston Scientific Corporation (22-26%)
Boston Scientific dominates the GI stent market with AI-powered precision deployment systems, self-expanding metal and plastic stents, and drug-eluting stent technology for improved patient outcomes.
Cook Medical (14-18%)
Cook Medical specializes in biodegradable and self-expanding GI stents, leveraging AI-assisted imaging for accurate placement and enhanced procedural efficiency.
Medtronic Plc (12-16%)
Medtronic leads in AI-driven gastrointestinal stent development, integrating advanced biocompatible materials and fluoroscopic guidance for optimal positioning.
Becton, Dickinson and Company (BD) (8-12%)
BD focuses on minimally invasive GI stent solutions with AI-assisted real-time patient monitoring, improving treatment for biliary and colonic strictures.
Taewoong Medical Co., Ltd. (6-10%)
Taewoong Medical provides high-performance GI stents, utilizing AI-powered deployment mechanisms and precision engineering for patient-specific solutions.
Other Key Players (30-40% Combined)
Several medical technology firms, endoscopy equipment manufacturers, and biotech companies contribute to next-generation GI stent innovations, AI-powered procedural enhancements, and biocompatible stent materials. Key contributors include:
The overall market size for the gastrointestinal stent market was USD 530.6 Million in 2025.
The gastrointestinal stent market is expected to reach USD 889.4 Million in 2035.
The demand for gastrointestinal stents is expected to rise due to the increasing prevalence of gastrointestinal disorders, growing adoption of minimally invasive procedures, and advancements in stent technology. The rising geriatric population and the expanding use of stents for palliative care in cancer patients are further boosting market growth. Additionally, improvements in biocompatible materials and stent design are enhancing treatment outcomes and driving adoption.
The top 5 countries driving the development of the gastrointestinal stent market are the USA, Germany, China, Japan, and France.
Self-Expanding Metal Stents and Plastic Stents are expected to command a significant share over the assessment period.
Gastrointestinal Stent Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
